Company / Current Liabilities
Trevi Therapeutics, Inc. Current Liabilities History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$10.5M
FY2024
5-year range
$5.6M / $13.4M
FY2020-FY2024
Trend
+80.4%
vs FY2023
Sector context
#206 of 213
Health Care
What the data says
Among 213 Health Care companies, Trevi Therapeutics, Inc. is in the top 3% for current liabilities. Improved from $13M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2024 with a 5-year CAGR of +15.1%.
Improved from $13M to $11M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -6.2%
- 5-Year CAGR
- +15.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $10.5M Sector average $1.6B
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.1%, indicating consistent growth.
- In FY2024, current liabilities increased 80.4% year-over-year.
- Ranks #206 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $10.5M | +80.4% |
| FY2023 | $5.8M | -56.5% |
| FY2022 | $13.4M | +5.3% |
| FY2021 | $12.7M | +129.1% |
| FY2020 | $5.6M | +6.8% |
| FY2019 | $5.2M | +94.3% |
| FY2018 | $2.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026